Encompass Health reaffirms 5-year growth targets; RCD affirmation >95% in Alabama

Encompass Health Corp

Five-year targets (2023-27): 6-10 de novos/year, 80-120 bed additions/year, 6-8% discharge CAGR.
Q3 volume trends positive; RCD in Alabama: ~440 records submitted, >95% affirmation rate vs 80% target.
H1 2023 adjusted EBITDA $478.6M; adjusted EPS from continuing ops $1.83 (diluted).
2023 interest expense estimate $145-155M; amortization approx $10M.
Non-GAAP measures reconciled; company reiterates focus on organic growth and regulatory initiatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.